Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit
The treatment effect in survival analysis is commonly quantified as the hazard ratio, and tested statistically using the standard log-rank test. Modern anticancer immunotherapies are successful in a proportion of patients who remain alive even after a long-term follow-up. This new phenomenon induces...
Uloženo v:
| Vydáno v: | JNCI : Journal of the National Cancer Institute Ročník 111; číslo 11; s. 1186 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.11.2019
|
| ISSN: | 1460-2105, 1460-2105 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The treatment effect in survival analysis is commonly quantified as the hazard ratio, and tested statistically using the standard log-rank test. Modern anticancer immunotherapies are successful in a proportion of patients who remain alive even after a long-term follow-up. This new phenomenon induces a nonproportionality of the underlying hazards of death.
The properties of the net survival benefit were illustrated using the dataset from a trial evaluating ipilimumab in metastatic melanoma. The net survival benefit was then investigated through simulated datasets under typical scenarios of proportional hazards, delayed treatment effect, and cure rate. The net survival benefit test was computed according to the value of the minimal survival difference considered clinically relevant. As comparators, the standard and the weighted log-rank tests were also performed.
In the illustrative dataset, the net survival benefit favored ipilimumab [Δ(0) = 15.8%, 95% confidence interval = 4.6% to 27.3%, P = .006]. This favorable effect was maintained when the analysis was focused on long-term survival differences (eg, >12 months, Δ(12) = 12.5% (95% confidence interval = 4.4% to 20.6%, P = .002). Under the scenarios of a delayed treatment effect and cure rate, the power of the net survival benefit test compared favorably to the standard log-rank test power and was comparable to the power of the weighted log-rank test for large values of the threshold of clinical relevance.
The net long-term survival benefit is a measure of treatment effect that is meaningful whether or not hazards are proportional. The associated statistical test is more powerful than the standard log-rank test when a delayed treatment effect is anticipated. |
|---|---|
| AbstractList | The treatment effect in survival analysis is commonly quantified as the hazard ratio, and tested statistically using the standard log-rank test. Modern anticancer immunotherapies are successful in a proportion of patients who remain alive even after a long-term follow-up. This new phenomenon induces a nonproportionality of the underlying hazards of death.
The properties of the net survival benefit were illustrated using the dataset from a trial evaluating ipilimumab in metastatic melanoma. The net survival benefit was then investigated through simulated datasets under typical scenarios of proportional hazards, delayed treatment effect, and cure rate. The net survival benefit test was computed according to the value of the minimal survival difference considered clinically relevant. As comparators, the standard and the weighted log-rank tests were also performed.
In the illustrative dataset, the net survival benefit favored ipilimumab [Δ(0) = 15.8%, 95% confidence interval = 4.6% to 27.3%, P = .006]. This favorable effect was maintained when the analysis was focused on long-term survival differences (eg, >12 months, Δ(12) = 12.5% (95% confidence interval = 4.4% to 20.6%, P = .002). Under the scenarios of a delayed treatment effect and cure rate, the power of the net survival benefit test compared favorably to the standard log-rank test power and was comparable to the power of the weighted log-rank test for large values of the threshold of clinical relevance.
The net long-term survival benefit is a measure of treatment effect that is meaningful whether or not hazards are proportional. The associated statistical test is more powerful than the standard log-rank test when a delayed treatment effect is anticipated. The treatment effect in survival analysis is commonly quantified as the hazard ratio, and tested statistically using the standard log-rank test. Modern anticancer immunotherapies are successful in a proportion of patients who remain alive even after a long-term follow-up. This new phenomenon induces a nonproportionality of the underlying hazards of death.BACKGROUNDThe treatment effect in survival analysis is commonly quantified as the hazard ratio, and tested statistically using the standard log-rank test. Modern anticancer immunotherapies are successful in a proportion of patients who remain alive even after a long-term follow-up. This new phenomenon induces a nonproportionality of the underlying hazards of death.The properties of the net survival benefit were illustrated using the dataset from a trial evaluating ipilimumab in metastatic melanoma. The net survival benefit was then investigated through simulated datasets under typical scenarios of proportional hazards, delayed treatment effect, and cure rate. The net survival benefit test was computed according to the value of the minimal survival difference considered clinically relevant. As comparators, the standard and the weighted log-rank tests were also performed.METHODSThe properties of the net survival benefit were illustrated using the dataset from a trial evaluating ipilimumab in metastatic melanoma. The net survival benefit was then investigated through simulated datasets under typical scenarios of proportional hazards, delayed treatment effect, and cure rate. The net survival benefit test was computed according to the value of the minimal survival difference considered clinically relevant. As comparators, the standard and the weighted log-rank tests were also performed.In the illustrative dataset, the net survival benefit favored ipilimumab [Δ(0) = 15.8%, 95% confidence interval = 4.6% to 27.3%, P = .006]. This favorable effect was maintained when the analysis was focused on long-term survival differences (eg, >12 months, Δ(12) = 12.5% (95% confidence interval = 4.4% to 20.6%, P = .002). Under the scenarios of a delayed treatment effect and cure rate, the power of the net survival benefit test compared favorably to the standard log-rank test power and was comparable to the power of the weighted log-rank test for large values of the threshold of clinical relevance.RESULTSIn the illustrative dataset, the net survival benefit favored ipilimumab [Δ(0) = 15.8%, 95% confidence interval = 4.6% to 27.3%, P = .006]. This favorable effect was maintained when the analysis was focused on long-term survival differences (eg, >12 months, Δ(12) = 12.5% (95% confidence interval = 4.4% to 20.6%, P = .002). Under the scenarios of a delayed treatment effect and cure rate, the power of the net survival benefit test compared favorably to the standard log-rank test power and was comparable to the power of the weighted log-rank test for large values of the threshold of clinical relevance.The net long-term survival benefit is a measure of treatment effect that is meaningful whether or not hazards are proportional. The associated statistical test is more powerful than the standard log-rank test when a delayed treatment effect is anticipated.CONCLUSIONThe net long-term survival benefit is a measure of treatment effect that is meaningful whether or not hazards are proportional. The associated statistical test is more powerful than the standard log-rank test when a delayed treatment effect is anticipated. |
| Author | Roy, Pascal Péron, Julien Giai, Joris Munier, Stephane Ozenne, Brice Maucort-Boulch, Delphine Buyse, Marc Lambert, Alexandre Machingura, Abigirl Dalle, Stéphane |
| Author_xml | – sequence: 1 givenname: Julien surname: Péron fullname: Péron, Julien – sequence: 2 givenname: Alexandre surname: Lambert fullname: Lambert, Alexandre – sequence: 3 givenname: Stephane surname: Munier fullname: Munier, Stephane – sequence: 4 givenname: Brice surname: Ozenne fullname: Ozenne, Brice – sequence: 5 givenname: Joris surname: Giai fullname: Giai, Joris – sequence: 6 givenname: Pascal surname: Roy fullname: Roy, Pascal – sequence: 7 givenname: Stéphane surname: Dalle fullname: Dalle, Stéphane – sequence: 8 givenname: Abigirl surname: Machingura fullname: Machingura, Abigirl – sequence: 9 givenname: Delphine surname: Maucort-Boulch fullname: Maucort-Boulch, Delphine – sequence: 10 givenname: Marc surname: Buyse fullname: Buyse, Marc |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30838402$$D View this record in MEDLINE/PubMed |
| BookMark | eNplkD1PwzAYhC1URD9gYkceWUL9FeOOpSpQqYKBMkdO_Lp1SewSO5Xg11NBkZC45W547oYbop4PHhC6pOSGkgkfb33lxmb7STg5QQMqJMkYJXnvT-6jYYxbctCEiTPU50RxJQgbIDONEWJ0fo2Xwa-zFbQNfunavdvrGt-BB-tSxMHiRdN0HvBsA9XbLjif8MJvXOlSaCN-_V5IG8BPkP71z9Gp1XWEi6OP0Op-vpo9Zsvnh8VsusyqXJCUgTGEGCG5skB4ZS0wKriWmpeVAM6MVIcgIKdSapAlm9CKKMYkgC0lsBG6_pndteG9g5iKxsUK6lp7CF0sGFUqV1Le5gf06oh2ZQOm2LWu0e1H8XsM-wIqtGg1 |
| CitedBy_id | crossref_primary_10_1002_pst_2271 crossref_primary_10_1002_mef2_56 crossref_primary_10_1016_j_coisb_2024_100540 crossref_primary_10_1111_cas_14967 crossref_primary_10_3389_fphar_2023_1265953 crossref_primary_10_1177_0962280220966629 crossref_primary_10_1177_09622802211037067 crossref_primary_10_1001_jamanetworkopen_2025_2484 crossref_primary_10_1186_s13023_023_02819_x crossref_primary_10_1002_sim_9690 crossref_primary_10_1177_17407745231186081 crossref_primary_10_3390_cancers15184669 crossref_primary_10_1016_j_jclinepi_2024_111340 crossref_primary_10_1007_s12561_020_09268_1 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
| DBID | NPM 7X8 |
| DOI | 10.1093/jnci/djz030 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2105 |
| ExternalDocumentID | 30838402 |
| Genre | Journal Article |
| GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 08P 0R~ 1TH 29L 2WC 354 4.4 482 48X 5GY 5RE 5VS 5WD 70D 96U AABZA AACZT AAHTB AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWTL ABCQX ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPEJ ABPPZ ABPTD ABQLI ABQNK ABVGC ABXVV ABZBJ ACBMB ACGFO ACGFS ACGOD ACKOT ACNCT ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW AEGPL AEJOX AEKSI AEMDU AEMQT AENZO AEPUE AETBJ AEWNT AFAZI AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AFYAG AGINJ AGKEF AGORE AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG BAWUL BAYMD BCRHZ BEYMZ BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EMOBN ENERS F5P F8P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NOMLY NOYVH NPM NU- OAUYM OAWHX OBH OCB OCZFY ODMLO ODZKP OGEVE OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q.- Q1. Q5Y R44 RD5 RNS ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TMA TR2 TWZ UDS UPT VVN W8F WH7 WOQ X7H YAYTL YKOAZ YQT YXANX ZKX ZRR ZY1 ~91 ~H1 7X8 |
| ID | FETCH-LOGICAL-c540t-edd00d4638fe03cffe2143a6a3bc4e32d68bc44e5166ae6b291c08226eefb6e2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000501732600012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2105 |
| IngestDate | Thu Oct 02 16:03:40 EDT 2025 Mon Jul 21 06:03:06 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| License | The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-edd00d4638fe03cffe2143a6a3bc4e32d68bc44e5166ae6b291c08226eefb6e2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/jnci/article-pdf/111/11/1186/30490958/djz030.pdf |
| PMID | 30838402 |
| PQID | 2188586675 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2188586675 pubmed_primary_30838402 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-11-01 |
| PublicationDateYYYYMMDD | 2019-11-01 |
| PublicationDate_xml | – month: 11 year: 2019 text: 2019-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JNCI : Journal of the National Cancer Institute |
| PublicationTitleAlternate | J Natl Cancer Inst |
| PublicationYear | 2019 |
| SSID | ssj0000924 |
| Score | 2.4079213 |
| Snippet | The treatment effect in survival analysis is commonly quantified as the hazard ratio, and tested statistically using the standard log-rank test. Modern... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1186 |
| Title | Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30838402 https://www.proquest.com/docview/2188586675 |
| Volume | 111 |
| WOSCitedRecordID | wos000501732600012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ3dS8MwEMCDOhFf_P6YX0TwNaxL2qx5Eh0OB64M3MPeSptetBPaaTsf_Ou9tB17EEHwpRRKIKSXu9_l7nKE3HAPeoJ3BQOddG2Y0Wdx5EkWOwpcFRnhKl01m-gFgT-dqnFz4FY0aZVLnVgp6iTX9oy8g6bI93yJfHs7f2e2a5SNrjYtNNZJSyDK2JSu3nR1W7ij6qa2rnQYujZeU5-HTnxnlum0k8y-qvTn39iysjGD3f_Obo_sNHRJ72px2CdrkB2QrVETPz8kSR3jRXNFn_LshU1QL9PnBaoLFDh6j3rPpGVBc0OHtm4EaP8V9Ns8T7OSDrPXNE5tcx5a5RlQREcaQPlj_BGZDB4m_UfW9FlgGnmtZJAkjpO4uBMNOEIbAxwpKpKRiLULgifSxxcXvK6UEciYq662F8VLABNL4MdkI8szOCXUMwoBgEeKI9fgV6XR2qGfitQTawd0m1wvly9EMbaxiSiDfFGEqwVsk5P6H4Tz-r6NUCAmoh_Kz_4w-pxsI9KoulrwgrQMbmK4JJv6s0yLj6tKPvAZjEffS9_HJg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessing+Long-Term+Survival+Benefits+of+Immune+Checkpoint+Inhibitors+Using+the+Net+Survival+Benefit&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=P%C3%A9ron%2C+Julien&rft.au=Lambert%2C+Alexandre&rft.au=Munier%2C+Stephane&rft.au=Ozenne%2C+Brice&rft.date=2019-11-01&rft.issn=1460-2105&rft.eissn=1460-2105&rft.volume=111&rft.issue=11&rft.spage=1186&rft_id=info:doi/10.1093%2Fjnci%2Fdjz030&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2105&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2105&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2105&client=summon |